柳叶刀TheLancet|柳叶刀-全球健康|国产HPV疫苗可为中国宫颈癌预防带来可观的经济回报( 二 )


柳叶刀TheLancet|柳叶刀-全球健康|国产HPV疫苗可为中国宫颈癌预防带来可观的经济回报
本文插图

Figure 2:Cost-effectiveness acceptability curves for all strategies
Intervention strategies that never have the highest probability of being cost-effective within the willingness-to-pay threshold of three-times the Chinese per-capita GDP are represented in grey. VIA=visual inspection with acetic acid. QALYs=quality-adjusted life-years. GDP=gross domestic product.
若中国响应世界卫生组织在全球范围内消除宫颈癌的目标 , 启动常规的适龄女性HPV疫苗接种计划 , 疫苗价格很可能进一步下调 。 该研究表明 , 当疫苗接种总成本降低至50美元时 , 即使以1倍中国人均GDP作为支付意愿阈值 , 疫苗接种结合筛查的方案也将比对应的单独筛查方案更具成本效果 。 当疫苗接种总成本大幅降低至10美元时 , 只有在支付意愿非常低的情况下(约
柳叶刀TheLancet|柳叶刀-全球健康|国产HPV疫苗可为中国宫颈癌预防带来可观的经济回报
本文插图
【柳叶刀TheLancet|柳叶刀-全球健康|国产HPV疫苗可为中国宫颈癌预防带来可观的经济回报】

Figure 3:Cost-effectiveness acceptability curves for all strategies at various costs of vaccination
Intervention strategies that never have the highest probability of being cost-effective within the willingness-to-pay threshold of three-times the Chinese per-capita GDP are represented in grey. VIA=visual inspection with acetic acid. QALY=quality adjusted life-year. GDP=gross domestic product.
从卫生经济学角度考虑 , 中国现阶段应采取普遍的宫颈癌预防策略 。 青少年女性HPV疫苗接种结合成年女性每隔5年进行一次careHPV筛查是当前成本效果最优的方案 。 进一步降低国产HPV疫苗价格 , 将为中国宫颈癌免疫预防带来更高的经济回报 。 该项研究成果可为当前中国宫颈癌防控策略制定提供重要参考依据 , 对推动中国适龄女性普遍HPV疫苗接种计划的实施具有重要意义 。 END
参考文献
1.Bruni L Albero G Serrano B et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the world. Summary report.
https://hpvcentre.net/statistics/reports/XWX.pdf?t=1596108932106 Date: 22 January 2019 Date accessed: June 5, 2019
2.WHO Comprehensive cervical cancer control: a guide to essential practice. 2nd edn. World Health Organization, Geneva2014
7.Qiao YL Wu T Li CR et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomised clinical trial. J Natl Cancer Inst. 2019; 112: 145-153
8.Zhu FC Chen W Hu YM et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer. 2014; 135: 2612-2622
*中文翻译仅供参考 , 所有内容以英文原文为准 。


推荐阅读